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Abstract
Background: Giant cell tumors are rare neoplasms, representing less than 5% of all bone tumors. The vast majority
of giant cell tumors occurs in extremity sites and is treated by surgery alone. However, a small percentage occurs
in pelvis, spine or skull bones, where complete resection is challenging. Radiation therapy seems to be an option
in these patients, despite the lack of a generally accepted dose or fractionation concept. Here we present a series
of five cases treated with high dose IMRT.
Patients and Methods: From 2000 and 2006 a total of five patients with histologically proven benign giant cell
tumors have been treated with IMRT in our institution. Two patients were male, three female, and median age was
30 years (range 20 – 60). The tumor was located in the sacral region in four and in the sphenoid sinus in one
patient. All patients had measurable gross disease prior to radiotherapy with a median size of 9 cm. All patients
were treated with IMRT to a median total dose of 64 Gy (range 57.6 Gy to 66 Gy) in conventional fractionation.
Results: Median follow up was 46 months ranging from 30 to 107 months. Overall survival was 100%. One patient
developed local disease progression three months after radiotherapy and needed extensive surgical salvage. The
remaining four patients have been locally controlled, resulting in a local control rate of 80%. We found no
substantial tumor shrinkage after radiotherapy but in two patients morphological signs of extensive tumor necrosis
were present on MRI scans. Decline of pain and/or neurological symptoms were seen in all four locally controlled
patients. The patient who needed surgical salvage showed markedly reduced pain but developed functional
deficits of bladder, rectum and lower extremity due to surgery. No severe acute or late toxicities attributable to
radiation therapy were observed so far.
Conclusion: IMRT is a feasible option in giant cells tumors not amendable to complete surgical removal. In our
case series local control was achieved in four out of five patients with marked symptom relief in the majority of
cases. No severe toxicity was observed.
Background
Giant cell tumors of bone are usually benign tumors,
however they can be locally aggressive and in some
cases malignant transformation or metastatic disease
occurs [1,2]. They account for approximately 5% of all
primary bone tumors and about 20% of benign bone
tumors [1]. The majority of these tumors is located in
the long bones of the extremities, however a small pro-
portion (< 10%) occurs in the pelvis, spine or skull base
[1,2]. Usually patients present with small lesions after a
brief history of swelling or pain but especially in the
sacral region, giant cell tumors can reach an enormous
size and result in massive pain in combination with
severe neurological deficits. The standard of care for
giant cell tumors is function-preserving surgery [3].
After complete resection, local control is achieved in 85-
90% of all cases [3], but incomplete resection is fre-
quently associated with tumor recurrence in up to 50%
of the cases [4]. Despite the improvements in surgical
techniques, complete tumor removal without major
functional deficits remains challenging in some regions,
especially sacral or pelvic bones, spine or skull base [4].
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Therefore primary radiotherapy has been advocated as
an alternative treatment in patients suffering from giant
cell tumors in these regions, although concerns about
local side effects of radiotherapy with appropriate doses
have been raised in the past [5,6]. As radiotherapy tech-
niques have extensively evolved in the last decades,
including the development of three-dimensional confor-
mal radiotherapy with megavoltage energies and even
intensity-modulated and image-guided radiotherapy, the
possibility to apply high doses with less toxicity and
optimal sparing of critical structures is now widely avail-
able. Here we report our experience with intensity-
modulated radiotherapy in the treatment of giant cell
tumors occurring outside the extremities in combination
with a short review of the literature.
Patients and Methods
Between 2000 and 2006 a total of five patients with
giant cell tumors have been treated with intensity
modulated radiotherapy in our institution. All tumors
were histologically proven before start of the treatment.
All patients except one with a giant cell tumor in the
sphenoid sinus suffered from large tumors in the sacral
region. Three tumors were judged primarily irresectable,
and one patient had undergone a subtotal resection
prior to radiotherapy. One patient suffered from a local
recurrence after initial surgery and embolisation and
received another embolisation and a subtotal resection
of the recurrence before irradiation. All patients with
tumors in the sacral region suffered from massive pain
and sensory neurological deficits prior to radiotherapy.
For detailed patient characteristics see table 1.
All patients were treated with IMRT using the step-
and-shoot approach [7]. For treatment planning, patients
were fixed in an individually manufactured precision
head and body mask made of Scotch cast® (3 M, St.Paul,
Minneapolis, MN) or an individually fixed vacuum pil-
low in order to immobilize the body. With this immobi-
lization system attached to the stereotactic base frame,
we performed contrast-enhanced CT- and MRI-images
under stereotactic conditions, with a slice thickness of 3
mm. We scanned the whole treatment region with a
superior and inferior margin of at least 3 cm. After
stereotactic image fusion based on the localizer-derived
coordinate system [8,9], all critical structures as well as
the target volumes were defined on each slice of the
three-dimensional data cube. The gross tumor volume
(GTV) was defined as the macroscopic tumor visible on
CT- and MRI-scans. For the clinical target volume
(CTV) a margin of 1-2 cm was added. In cases of subto-
tal resections the whole resection cavity was included
into the CTV. Inverse treatment-planning was per-
formed using the KonRad software developed at the
German Cancer Research Center (DKFZ), which is con-
nected to the 3D planning program VIRTUOS to calcu-
late and visualize the 3D dose distribution. The IMRT
treatment planning process has been described in detail
previously [10-13]. Radiation treatment was delivered by
a Siemens accelerator (Primus, Siemens, Erlangen, Ger-
many) with 6 or 15 MV photons using an integrated
motorized multileaf collimator (MLC) for the step-and-
shoot technique automatically delivering the sequences.
The total doses were prescribed to the median of the
target volume and usually the 95% isodose surrounded
the CTV. The prescribed dose ranged from 57.6 Gy to
66 Gy with a median dose of 64 Gy, applied in conven-
tional fractionation (single dose 1.8-2 Gy, five fractions
per week). Examples for dose distributions and DVH
data are shown in Figure 1 and 2. Time to event data
was calculated from the first day of radiation treatment.
Local progression was defined as tumor growth on
repeated CT or MRI scans or increase of clinical symp-
toms which needed surgical salvage.
Results
All patients were followed with clinical examination and
MRI scans in our institution or the referring hospital on
a regular basis. Median follow up was 46 months, ran-
ging from 30 to 107 months.
Local control and salvage surgery
Four out of five patients have been locally controlled
without clinical or radiographic signs of progression,
resulting in an overall local control rate of 80%. One
patient with a biopsy proven primary giant cell tumor of
the sacral region developed a progression of clinical
Table 1 Patients, treatment and outcome
Pat. Age Gender Local. Size Treatm. Dose f/u Local Recurrence Clinical Outcome Radiographic Outcome
1 60 F Sacral 3,5 E+S*+RT 64 107 No Minor improvement No change
2 52 F Sacral 9 RT 64 46 3 months
(salvage)
Progressive symptoms No change
3 23 M Sphenoid 2,5 S*+RT 57,6 63 No No residual symptoms No change
4 20 M Sacral 10 RT 66 44 No Major improvement Tumor necrosis
5 30 M Sacral 11 RT 60 35 No Major improvement Tumor necrosis
age [years], M: male, F: female, size [cm], S*: surgery (subtotal resection), E: embolisation, RT: radiotherapy, dose [Gy], f/u: follow up [months]
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symptoms in the meaning of pain, paralysis of the leg
and bladder/rectal dysfunction without tumor progres-
sion on MRI scan three months after radiotherapy. She
received salvage surgery which included complete
removal of the tumor and is currently alive without evi-
dence of disease and marked pain relief, but suffers
from impaired extremity function, complete loss of blad-
der function and a permanent descendostoma.
Treatment toxicity
Acute toxicity related to the radiation treatment was of
minor grade in all cases. No acute toxicity of grade > 1
according to RTOG was observed. In detail, three
patients suffered from mild skin erythema, one from mild
alopecia, one from diarrhea, one from urgency and one
from mild conjunctivitis. All acute toxicities resolved
spontaneously. Beside from mild skin hyperpigmentation
in the irradiated areas in two patients, no late toxicities
attributable to radiation therapy were observed so far.
Clinical outcome
Reduction of pain was observed in four out of five
patients already during radiotherapy. Considering the
long term follow up excluding the patient with salvage
surgery three months after radiotherapy, one patient
showed a minor, two patients a major improvement of
their symptoms and one patient is free of symptoms.
Improvement included not only reduced pain but also a
decrease of the sensory neurological deficits in two
patients.
Radiographic outcome
All patients were monitored closely with repeated MRI
imaging during the follow up period. None of the
patients showed a substantial reduction of tumor size
after radiotherapy, but in two patients typical radio-
graphic signs of massive central tumor necrosis were
found as reaction on radiotherapy during the further fol-
low up (see figure 3).
Discussion
The mainstay of treatment of giant cell tumors of the
bone is complete surgical excision. Especially in patients
with extremity tumors, this treatment results in high
local control rates of more than 85% [3] without major
complications or functional deficits. However, a small
proportion of patients suffers from large giant cell
tumors of sacral bone, spine or skull base. In these
regions of the body, complete surgical removal without
major functional deficits is challenging or sometimes
impossible and recurrence rates of about 50% have been
reported after surgical treatment with intralesional mar-
gins [4]. Systemic treatment options are limited,
although there seems to be some progress through
improved understanding of the molecular mechanisms
in the development of giant cell tumors. As they are
rich in stromal cells that express RANKL, a key media-
tor of osteoclast activation [14], increasing interest has
been paid to monoclonal antibodies against RANKL, for
example denosumab. A pilot study in 37 patients
showed a response rate of 86% and functional
Figure 1 Sagittal dose distribution and DVH information in patient 5. graphs: PTV (3), rectum (4), bladder (5)
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improvements including reduced pain in 84% of the
patients suffering from giant cell tumors treated with
denosumab [14]. However, no long term data about the
recurrence rate, functional outcome and long term toxi-
city with this promising approach exists so far and
therefore further investigation is needed to establish the
value of this treatment option. Therefore primary radio-
therapy has to be considered as an alternative treatment
in patients with giant cell tumors not suitable for com-
plete resection, although based on small patient series,
collected over long time periods, with wide variations in
fractionation, total dose and radiation techniques
[1-4,15-20].
Beside the limited data for this treatment approach,
radiotherapy has been criticized in the past also because
of low rates of local control in some series and concerns
about side effects and induction of malignant transfor-
mation [2,5,6]. Careful examination reveals that many of
these series have been conducted in the 2-D era of
radiotherapy and radiodiagnostics more than 15 years
Figure 2 Transversal, coronar and sagittal dose distribution and DVH information in patient 3. graphs: PTV (1), left eye (2), right eye (3),
right optic nerve (4), left optic nerve (5), chiasma (6), brainstem (7), spinal cord (8)
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ago. This implicates not only a high possibility for geo-
graphical misses due to the use of plain radiographs for
tumor localisation, which could have resulted in
decreased coverage of the tumors by radiation therapy
and therefore decreased local control, but also the use
of orthovoltage techniques with low energies, resulting
in high toxicity due to the unfavourable dose distribu-
tion and probably increased rates of secondary malig-
nancies [21].
As radiation therapy techniques have strongly
improved in the last decades including the wide-spread
implementation of three-dimensional conformal radio-
therapy and even intensity-modulated and image-guided
radiotherapy, these lesions can now be treated with high
doses in the absence of major acute and late side effects
to the adjacent normal tissues. In our case series, five
patients were treated with intensity modulated radiother-
apy to a median dose of 64 Gy, which resulted in a local
control rate of 80%. Although all primary tumors have
been localized in regions with directly adjacent organs at
risk, like rectum, small bowel or the optic nervous sys-
tem, no severe acute or late toxicity attributable to radia-
tion treatment has been observed so far. Other series
using modern radiation therapy techniques have reported
similar results. For example Feigenberg et al. [1] found a
local control rate of 77% in a series of 26 lesions with
three severe and four minor complications associated
with radiotherapy using doses of 35-55 Gy. Schwartz et
al. [15] reviewed the MGH experience and observed a
local control rate of 85% after radiotherapy with doses of
42-68 Gy. Seider at al. [3] presented a series from the
MD Anderson and found a local control rate of 70%
using doses of 36-66 Gy. Even after exclusion of all non-
extremity tumors and all patients with gross total resec-
tion prior to radiotherapy from these series, the results
do not differ distinctly (see table 2). Thus modern ima-
ging and radiation techniques offer the possibility of high
tumor control rates without major side effects.
Considering the issue of malignant transformation,
these concerns regarding radiation therapy, have mainly
been based on initial reports of transformation rates up
to 24% [6]. Other series using more modern radiother-
apy techniques found lower rates of 0-11% [1,4] and a
recent metaanalysis reported an incidence of less than
1% in patients treated with megavoltage radiation and
modern radiation therapy techniques [1]. Beside that,
malignant transformation and sarcoma induction have
also been reported in patients treated without radiation
at all. For example Dahlin et al. [22] reported the devel-
opment of sarcoma in 2 of 47 (4%) patients and
Mnaymneh et al. [23] even in 2 of 25 (8%) patients after
surgery. The appearance of malignant giant cell tumors
of bone or malignant foci inside benign giant cell
tumors has been described also in a small number of
patients [24,25], and pulmonary metastases can be
found in 2-9% of patients with benign giant cell tumors
[5,26-28]. Thus malignant transformation or the appear-
ance of metastases could be part of the disease itself in
a small proportion of cases and should not be attributed
unreflected to radiation treatment.
Figure 3 Development of central tumor necrosis in patient 4. left side: MRI before radiotherapy, right side: MRI 1 year after radiotherapy
with development of massive central necrosis
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To date there is no generally accepted fractionation or
dose concept for the treatment of giant cell tumors. A
clear dose-effect relationship has not been established
yet, but in some series higher doses resulted in
increased local control rates. For example, Feigenberg et
al. [1] found a significant increased local control rate of
86% with doses above 40 Gy compared to 67% with
lower doses. In contrast, Leggon et al. [4] did not find a
benefit in terms of local control comparing doses of <
45 Gy, 45-55 Gy and > 55 Gy in pelvic and sacral
lesions, but the overall local control rate in their series
was only about 50%. Malone et al. [2] found a local con-
trol rate of 83% in non-extremity lesions even using
doses as low as 35 Gy in 15 fractions. In our patients,
we attempted doses of 60-66 Gy, a dose range which
could be safely administered without major toxicities
based on our experiences in treating other sacral lesions
like chordoma or low grade chondrosarcoma using
IMRT in order to achieve maximal local control.
Although a wide dose range was reported in most of the
series, careful examination leads to the impression that
usually patients with radiation as sole treatment and
non-extremity lesions were treated with higher doses.
However, if dose escalation beyond doses of 45 Gy
increases local control, remains an open question based
on the available data.
Considering the clinical outcome of patients with giant
cell tumors treated by radiotherapy, only little informa-
tion is available in the literature. For example in the
series of Schwartz et al. [15], only three of thirteen
patients had neurological symptoms before treatment.
All three patients showed improved neurological function
after radiation therapy. Malone et al. [2] reported 7
patients with symptomatic disease before radiotherapy,
all have been ambulatory and independent after treat-
ment. In our series, all patients suffered from pain and/or
neurological deficits prior to radiotherapy. After treat-
ment, all patients showed some kind of improvement
except the patient who needed salvage surgery three
months after radiotherapy. One of the four patients is
free of symptoms, two had major improvements and one
a minor improvement. Thus radiotherapy cannot only
stop the locally destructive growth of giant cell tumors
but also decreases pain and other neurological symptoms
of the patients resulting in improved quality of life.
Considering the radiographic outcome of giant cell
tumors after radiotherapy, the available information in
the literature is even more scanty than for clinical out-
come. This may be linked to the use of two-dimensional
radiographs for diagnosis and follow up in most of the
older series. The appearance of bone sclerosis after
radiotherapy in most cases has been described by Seider
et al. [3], and tumor response in terms of involution or
ossification was observed in 4 of 9 patients in the series
reported by Leggon et al. [4]. In our series, MRI was
used for diagnostics and regular follow up in all patients.
In contrast to the mentioned results, we did not find
significant tumor volume shrinkage after treatment.
However, the absence of significant volume reduction is
a common feature of benign lesions treated by radio-
therapy, as shown in many other entities like menin-
gioma, desmoids or chordoma [29-31] and should not
be interpreted as a failure of treatment.
Conclusion
Radiotherapy carried out by modern techniques based
on modern imaging could be an alternative treatment
approach in patients with giant cell tumors not amend-
able to function-preserving surgery. High local control
rates without severe acute or late side effects and
improvement in clinical symptoms are achievable in the
majority of patients.
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Table 2 Literature overview
Author Year n f/u8 Size9 RT dose10 LR
Seider et al. [3] 1986 10 8 n.s. 45,5 30%
Schwartz et al. [15]1,2 1989 7 4 7 54 14%
Malone et al. [2]1,2 1995 5 19 7,5 357 20%
Feigenberg et al. [1]1,2 2003 15 10 n.s. 45 20%
Leggon et al. [4]1,3 2004 11 6 10 47,8 18%
Leggon et al. [4]1,3,4 2004 148 96 n.s. 47,85 47%
Own data 2009 5 4 9 64 20%
Selected reports dealing with non-extremity giant cell tumors treated with RT
alone or after subtotal resection, 1 : only patients with macroscopic residual
disease after surgery or primary treatment included, 2: only patients suffering
from non-extremity lesions included, 3 : only patients treated with RT
included, 4 : pooled literature analysis, 5 : mean dose, 6 : mean f/u calculated
of the entire cohort including patients without RT, 7 : single dose 2,4 Gy, 8 :
[years], 9 : [cm], 10 : median dose [Gy], LR: crude local failure rates, f/u: median
follow up
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